- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cate Lockhart, PharmD, PhD: Upcoming Research From the BBCIC
Cate Lockhart, PharmD, PhD, discusses the research reports the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) plans on releasing in 2020.
Transcript
We have a couple of really exciting projects that we're just gearing up to get going now.
One is another one of these infrastructure projects where we're looking at the data feasibility and the capabilities within our distributed research network administrator claims. It's often difficult to find, to identify, clinical outcomes. And cancer has a very specific set of outcomes that we're interested in. And so we're looking at how can we expand our existing data network, while still keeping the multistakeholder environment intact, to give us the capability to do the same kind of research that we're doing in nononcology products and translate that over into oncology.
So that's an infrastructure project that we're that we're working on now. And we are just launching our first full-scale comparative effectiveness study in the G-CSF [granulocyte colony-stimulating factor] products because we have enough utilization in in the US to allow us to do that. That'll take 18 months or so before we're really finished with that by the time we launch, but that's going to be a really interesting project and, and I think that's going to help define some of our future projects.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
